Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

NCT02580032 · View on ClinicalTrials.gov ↗

Study Summary

This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).

Interventions

  • OTHER No treatment given

Study Locations (20)

New York

  • Novo Nordisk Investigational Site — Albany
  • Novo Nordisk Investigational Site — Buffalo
  • Novo Nordisk Investigational Site — Mineola
  • Novo Nordisk Investigational Site — New York
  • Novo Nordisk Investigational Site — Spring Valley

Florida

  • Novo Nordisk Investigational Site — Margate
  • Novo Nordisk Investigational Site — Miami
  • Novo Nordisk Investigational Site — Tallahassee

Arizona

  • Novo Nordisk Investigational Site — Phoenix

Colorado

  • Novo Nordisk Investigational Site — Centennial

Delaware

  • Novo Nordisk Investigational Site — Wilmington

Georgia

  • Novo Nordisk Investigational Site — Atlanta

Illinois

  • Novo Nordisk Investigational Site — Wheaton

Iowa

  • Novo Nordisk Investigational Site — Iowa City

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2015-10-05
Est. Completion 2018-05-14

Sponsor

Novo Nordisk A/S

189 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02580032

The ClinicalTrials.gov registry entry for NCT02580032 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Growth Disorder appearing as the primary indexed condition, and to 1 intervention — of which No treatment given is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02580032 reports 20 study locations spanning 14 distinct geographic areas — top geographies include New York, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02580032 about?

NCT02580032 is a clinical study titled "Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)". This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood ...

What is the current status of trial NCT02580032?

This trial is currently completed. The enrollment target is 252 participants. The study started on 2015-10-05. Estimated completion is 2018-05-14.

What conditions does trial NCT02580032 study?

This clinical trial studies the following conditions: Growth Disorder, Growth Hormone Deficiency in Children. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02580032?

The interventions under investigation include: No treatment given (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02580032?

This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02580032 being conducted?

This trial has 20 study locations across Arizona, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial